Michigan Medicine convenes COVID-19 Vaccine and Therapeutics Task Force
Michigan Medicine has convened a multidisciplinary COVID-19 Vaccine and Therapeutics Task Force (CVTT) to develop an institutional strategy and operational plan for COVID-19 vaccines and therapeutics once FDA authorization is obtained.
It is anticipated that the FDA may provide Emergency Use Authorization of the first vaccine shortly, with availability as soon as December.
When final data is available as to the safety and efficacy of the COVID-19 vaccine, the CVTT will review and await the final CDC Advisory Committee on Immunization Practices recommendations. This will inform the recommendations put forth for COVID-19 vaccinations for Michigan Medicine employees.
While planning continues, the following is expected to guide initial vaccine allocation:
- Prioritization of health care workers who are (or will be) providing face-to-face services with patients, and who are at an increased risk for severe illness from COVID-19, including all ambulatory and inpatient staff and faculty.
- The critical importance of ensuring equitable access for those meeting criteria.
- Vaccination for Michigan Medicine employees in this early phase will be optional.
It is important for all employees to receive their flu shot now, ahead of the COVID-19 vaccine becoming available. The COVID-19 vaccine will not likely be co-administered.